CD19 and neoplasm: After multiple rounds of coculture, the tumor-killing ability of conventional CAR-T cells began to decline noticeably, in contrast to that of CD19-BBζ + CD2 CAR-T cells, which consistently displayed vigorous tumoricidal activity (Fig. 3H, I).